The FDA Just Made Ozempic More Expensive — Here’s How

While Americans struggle to afford life-changing medications, the Food and Drug Administration has made a decision that effectively forces U.S. patients to subsidize Denmark's booming economy. The FDA's recent declaration that the semaglutide shortage is "over" represents a staggering policy failure that benefits foreign pharmaceutical giants at the direct expense of American patients and healthcare innovation. This semaglutide (also known as GLP-1) is the key ingredient in weight loss and diabetes medicine that is reducing obesity across the country.

The numbers tell the story: Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, became the largest company in Europe at the end of 2023, after demand for Ozempic skyrocketed in just a few years. This meteoric rise has transformed not just the company but an entire nation. Novo Nordisk was responsible for more than half of the private sector job growth in Denmark, which now boasts one of Europe's fastest-growing economies. Pharmaceutical exports are driving half of the country's 2.5% GDP growth in 2023, and anticipated growth of 3.0% in 2024 and 2.9% this year.

The tiny port town of Kalundborg, home to fewer than 17,000 residents, has become an unlikely boomtown. Novo Nordisk is investing an eye-watering $8.6 billion in expanding its facilities in Kalundborg, a Danish town of less than 17,000 residents. While Danes enjoy lower interest rates, expanded public amenities, and a robust job market thanks to the influx of American dollars, Americans themselves face impossible choices about whether they can afford medication at all.

It’s important to remember that more than half of Novo Nordisk’s sales were in the United States, so the American market is extremely important for their continued growth, which single-handedly prevented a recession in Denmark.

Despite, or maybe because of, the importance of the American market, Ozempic’s list price is $900 a month, while Wegovy stands at $1,300 a month – an exorbitant sum for most Americans. For a while, there was an affordable alternative. When the federal government declared a shortage of semaglutide and allowed compounded options that sold for hundreds less than the name-brand products.

In February, leftover staff from the Biden Administration declared the shortage over, and gave compounding pharmacies a deadline to stop selling semaglutide options – in effect, raising the bill for the drug from less than $200 to more than $1,000.

 The FDA's decision carries devastating consequences for Americans who depend on these medications. Rural and underserved communities, which often relied on telehealth and compounding pharmacies when brand-name options were unavailable or inaccessible, will be disproportionately affected. Countless patients will be forced to abandon treatment due to cost barriers, leading to worsening health conditions and higher long-term healthcare costs.

The FDA's decision represents a profound failure of regulatory policy. Rather than protecting American interests, it has sacrificed affordable access to critical medications in favor of boosting a foreign pharmaceutical giant's profits and another country's economic growth.

A better approach would balance legitimate safety concerns with the need for market competition to control prices.

The FDA should immediately reassess its shortage determination and restore the ability of American compounding pharmacies to produce affordable alternatives. Insurance reforms should expand coverage for these medications, and policy frameworks should be established to ensure Americans aren't paying premium prices that subsidize European healthcare systems.

America's regulatory agencies should prioritize the health and financial well-being of American patients over the economic interests of foreign corporations and countries. The current arrangement—where Americans pay the highest prices in the world for medications that fuel another nation's economic boom—is simply untenable.

It's time for policymakers to act. Americans deserve access to affordable, life-changing medications without being forced to bankroll Denmark's economic miracle. The FDA's decision on semaglutide isn't just bad healthcare policy—it's a failure to protect American interests in favor of subsidizing foreign prosperity.